Abstract A092: Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA)

Abstract Introduction: Ovarian cancer is still the leading cause of death among all gynaecological cancers in developed countries. High-grade serous ovarian cancer patients (HGSOC) with platinum-resistant or refractory disease have limited therapeutic options thus very poor prognosis. Early identification of these patients could limit useless undesirable effects and explore more effective therapeutic options. Short-term ex vivo assays might address such unmet needs, providing a truly personalized approach. Methods: Eleven advanced HGSOC patients have been enrolled. At the time of primary debulking surgery, tumor biopsies from different tumor anatomic sites (omentum and/or peritoneum) have been collected and divided in two sections: one section has been included in OCT and then processed for H 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84 (5 Suppl₂): Abstract nr A092.